This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34.
In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography.
The WHO Initiative for Vaccine Research (IVR) Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on priorities in malaria vaccine research and development (R&D).
A nested primer set that targets one of the P. knowlesi small-subunit rRNA genes was validated for specificity and for sensitivity of detection of <10 parasite genomes.
As P. vivax is more prevalent in seasonal climates and P. falciparum in areas of more consistent rainfall, it is postulated that there will be a correlation between the ratio of vivax:falciparum and the El Niño Southern Oscillation (ENSO), which affects sea surface temperatures and rainfall.
Apical membrane antigen-1 is a candidate for inclusion in a vaccine for the human malaria parasite Plasmodium vivax.
In the Republic of Korea (ROK), military antimalarial chemoprophylaxis was initiated in 1997. Although chemoprophylaxis reduces malaria cases, long-term chemoprophylaxis could increase resistance. In this study, the recurrence rate of vivax malaria was investigated.